

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
July 19, 2016**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Audentes Therapeutics, Inc.

File No. 333-208842 - CF#33234

Audentes Therapeutics, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on January 4, 2016 and amended on June 16, 2016.

Based on representations by Audentes Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.12	through November 18, 2025
Exhibit 10.13	through November 18, 2025
Exhibit 10.14	through November 18, 2025
Exhibit 10.15	through November 18, 2025
Exhibit 10.16	through November 18, 2025
Exhibit 10.17	through December 28, 2025
Exhibit 10.18	through June 16, 2026

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary